Your browser doesn't support javascript.
Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds.
Simões, Eric A F; Klein, Nicola P; Sabharwal, Charu; Gurtman, Alejandra; Kitchin, Nicholas; Ukkonen, Benita; Korbal, Piotr; Zou, Jing; Xie, Xuping; Sarwar, Uzma N; Xu, Xia; Lockhart, Stephen; Cunliffe, Luke; Lu, Claire; Ma, Hua; Swanson, Kena A; Koury, Kenneth; Shi, Pei-Yong; Cooper, David; Türeci, Ó¦zlem; Jansen, Kathrin U; Sahin, Ugur; Gruber, William C.
  • Simões EAF; Children's Hospital Colorado and University of Colorado School of Medicine, Aurora, CO, USA.
  • Klein NP; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California, Oakland, CA, USA.
  • Sabharwal C; Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.
  • Gurtman A; Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.
  • Kitchin N; Vaccine Research and Development, Pfizer Ltd, Hurley, UK.
  • Ukkonen B; Espoo Vaccine Research Clinic, Tampere University, Espoo, Finland.
  • Korbal P; Osrodek Badan Klinicznych In-Vivo, Bydgoszcz-Torun, Poland.
  • Zou J; Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
  • Xie X; Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
  • Sarwar UN; Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.
  • Xu X; Vaccine Research and Development, Pfizer Inc, Collegeville, PA, USA.
  • Lockhart S; Vaccine Research and Development, Pfizer Ltd, Hurley, UK.
  • Cunliffe L; Vaccine Research and Development, Pfizer Ltd, Hurley, UK.
  • Lu C; Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.
  • Ma H; Vaccine Research and Development, Pfizer Inc, Collegeville, PA, USA.
  • Swanson KA; Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.
  • Koury K; Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.
  • Shi PY; Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
  • Cooper D; Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.
  • Türeci Ó¦; BioNTech, Mainz, Germany.
  • Jansen KU; Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.
  • Sahin U; BioNTech, Mainz, Germany.
  • Gruber WC; Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.
J Pediatric Infect Dis Soc ; 12(4): 234-238, 2023 Apr 28.
Article in English | MEDLINE | ID: covidwho-2281524
ABSTRACT
In this ongoing study, substantially increased ancestral SARS-CoV-2 neutralizing responses were observed 1 month after a third 10-µg BNT162b2 dose given to 5 to 11-year olds versus neutralizing responses post-dose 2. After dose 3, increased neutralizing responses against Omicron BA.1 and BA.4/BA.5 strains were also observed. The safety/tolerability profile was acceptable. (NCT04816643).
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / BNT162 Vaccine Topics: Vaccines / Variants Limits: Humans Language: English Journal: J Pediatric Infect Dis Soc Year: 2023 Document Type: Article Affiliation country: Jpids

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / BNT162 Vaccine Topics: Vaccines / Variants Limits: Humans Language: English Journal: J Pediatric Infect Dis Soc Year: 2023 Document Type: Article Affiliation country: Jpids